Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 242

1.

Recent Advances in the Management of Autosomal Dominant Polycystic Kidney Disease.

Chebib FT, Torres VE.

Clin J Am Soc Nephrol. 2018 Jul 26. pii: CJN.03960318. doi: 10.2215/CJN.03960318. [Epub ahead of print] Review.

PMID:
30049849
2.

Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.

Edwards ME, Chebib FT, Irazabal MV, Ofstie TG, Bungum LA, Metzger AJ, Senum SR, Hogan MC, El-Zoghby ZM, Kline TL, Harris PC, Czerwiec FS, Torres VE.

Clin J Am Soc Nephrol. 2018 Aug 7;13(8):1153-1161. doi: 10.2215/CJN.01520218. Epub 2018 Jul 19.

PMID:
30026287
3.

Polycystic Kidney Disease, Autosomal Dominant.

Harris PC, Torres VE.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018.
2002 Jan 10 [updated 2018 Jul 19].

4.

Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease.

Dad T, Abebe KZ, Bae KT, Comer D, Torres VE, Czarnecki PG, Schrier RW, Steinman TI, Moore CG, Chapman AB, Kaya D, Tao C, Braun WE, Winklhofer FT, Brosnahan G, Hogan MC, Miskulin DC, Rahbari Oskoui F, Flessner MF, Perrone RD.

Kidney Int Rep. 2018 Jan 6;3(3):619-624. doi: 10.1016/j.ekir.2017.12.011. eCollection 2018 May.

5.

Monoallelic Mutations to DNAJB11 Cause Atypical Autosomal-Dominant Polycystic Kidney Disease.

Cornec-Le Gall E, Olson RJ, Besse W, Heyer CM, Gainullin VG, Smith JM, Audrézet MP, Hopp K, Porath B, Shi B, Baheti S, Senum SR, Arroyo J, Madsen CD, Férec C, Joly D, Jouret F, Fikri-Benbrahim O, Charasse C, Coulibaly JM, Yu AS, Khalili K, Pei Y, Somlo S, Le Meur Y, Torres VE; Genkyst Study Group; HALT Progression of Polycystic Kidney Disease Group; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease, Harris PC.

Am J Hum Genet. 2018 May 3;102(5):832-844. doi: 10.1016/j.ajhg.2018.03.013. Epub 2018 Apr 26.

PMID:
29706351
6.

Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade?

Brosnahan GM, Abebe KZ, Moore CG, Bae KT, Braun WE, Chapman AB, Flessner MF, Harris PC, Hogan MC, Perrone RD, Rahbari-Oskoui FF, Steinman TI, Torres VE, The Halt Pkd Investigators.

Curr Hypertens Rev. 2018;14(1):39-47. doi: 10.2174/1573402114666180322110209.

7.

The Value of Genetic Testing in Polycystic Kidney Diseases Illustrated by a Family With PKD2 and COL4A1 Mutations.

Cornec-Le Gall E, Chebib FT, Madsen CD, Senum SR, Heyer CM, Lanpher BC, Patterson MC, Albright RC, Yu AS, Torres VE; HALT Progression of Polycystic Kidney Disease Group Investigators, Harris PC.

Am J Kidney Dis. 2018 Aug;72(2):302-308. doi: 10.1053/j.ajkd.2017.11.015. Epub 2018 Feb 1.

PMID:
29395486
8.

Tolvaptan in Later-Stage Polycystic Kidney Disease.

Torres VE, Gansevoort RT, Czerwiec FS.

N Engl J Med. 2018 Feb 1;378(5):489-490. doi: 10.1056/NEJMc1716478. No abstract available.

9.

European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care: European ADPKD Forum and Multispecialist Roundtable participants.

Harris T, Sandford R, de Coninck B, Devuyst O, Drenth JPH, Ecder T, Kent A, Gansevoort RT, Górriz JL, Ong ACM, Pirson Y, Torres VE, Budde K, Clément D, Derchi LE, Eleftheroudi M, Levtchenko E, Peters D, Van Poppel H, Vanholder R.

Nephrol Dial Transplant. 2017 Dec 22. doi: 10.1093/ndt/gfx327. [Epub ahead of print]

10.

Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials.

Brosnahan GM, Abebe KZ, Moore CG, Rahbari-Oskoui FF, Bae KT, Grantham JJ, Schrier RW, Braun WE, Chapman AB, Flessner MF, Harris PC, Hogan MC, Perrone RD, Miskulin DC, Steinman TI, Torres VE; HALT-PKD Trial Investigators.

Am J Kidney Dis. 2018 May;71(5):666-676. doi: 10.1053/j.ajkd.2017.10.023. Epub 2018 Jan 3.

PMID:
29306517
11.

Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease.

Yu ASL, Shen C, Landsittel DP, Harris PC, Torres VE, Mrug M, Bae KT, Grantham JJ, Rahbari-Oskoui FF, Flessner MF, Bennett WM, Chapman AB; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP).

Kidney Int. 2018 Mar;93(3):691-699. doi: 10.1016/j.kint.2017.09.027. Epub 2017 Dec 28.

PMID:
29290310
12.

Autosomal Dominant Polycystic Kidney Patients May Be Predisposed to Various Cardiomyopathies.

Chebib FT, Hogan MC, El-Zoghby ZM, Irazabal MV, Senum SR, Heyer CM, Madsen CD, Cornec-Le Gall E, Behfar A, Harris PC, Torres VE.

Kidney Int Rep. 2017 Jun 6;2(5):913-923. doi: 10.1016/j.ekir.2017.05.014. eCollection 2017 Sep.

13.

ADPKD Progression in Patients With No Apparent Family History and No Mutation Detected by Sanger Sequencing.

Braun WE, Abebe KZ, Brosnahan G, Patterson CG, Chapman AB, Harris PC, Hogan MC, Perrone RD, Torres VE, Miskulin DC, Steinman TI, Winklhofer FT, Rahbari-Oskoui FF, Czarnecki PG, Bae KT, Grantham JJ, Flessner MF, Schrier RW.

Am J Kidney Dis. 2018 Feb;71(2):294-296. doi: 10.1053/j.ajkd.2017.09.008. Epub 2017 Dec 2. No abstract available.

PMID:
29203126
14.

A Drug Development Tool for Trial Enrichment in Patients With Autosomal Dominant Polycystic Kidney Disease.

Perrone RD, Mouksassi MS, Romero K, Czerwiec FS, Chapman AB, Gitomer BY, Torres VE, Miskulin DC, Broadbent S, Marier JF.

Kidney Int Rep. 2017 Feb 21;2(3):451-460. doi: 10.1016/j.ekir.2017.02.011. eCollection 2017 May.

15.

Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease.

Perrone RD, Mouksassi MS, Romero K, Czerwiec FS, Chapman AB, Gitomer BY, Torres VE, Miskulin DC, Broadbent S, Marier JF.

Kidney Int Rep. 2017 Jan 16;2(3):442-450. doi: 10.1016/j.ekir.2017.01.003. eCollection 2017 May. Erratum in: Kidney Int Rep. 2018 May 22;3(4):1015.

16.

Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease.

Nowak KL, You Z, Gitomer B, Brosnahan G, Torres VE, Chapman AB, Perrone RD, Steinman TI, Abebe KZ, Rahbari-Oskoui FF, Yu ASL, Harris PC, Bae KT, Hogan M, Miskulin D, Chonchol M.

J Am Soc Nephrol. 2018 Feb;29(2):571-578. doi: 10.1681/ASN.2017070819. Epub 2017 Nov 8.

PMID:
29118087
17.

Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.

Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais JD, Czerwiec FS, Sergeyeva O; REPRISE Trial Investigators.

N Engl J Med. 2017 Nov 16;377(20):1930-1942. doi: 10.1056/NEJMoa1710030. Epub 2017 Nov 4.

PMID:
29105594
18.

Genetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases.

Cornec-Le Gall E, Torres VE, Harris PC.

J Am Soc Nephrol. 2018 Jan;29(1):13-23. doi: 10.1681/ASN.2017050483. Epub 2017 Oct 16.

PMID:
29038287
19.

Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial.

Cornec-Le Gall E, Blais JD, Irazabal MV, Devuyst O, Gansevoort RT, Perrone RD, Chapman AB, Czerwiec FS, Ouyang J, Heyer CM, Senum SR, Le Meur Y, Torres VE, Harris PC.

Nephrol Dial Transplant. 2017 Jul 19. doi: 10.1093/ndt/gfx188. [Epub ahead of print]

20.

Common Elements in Rare Kidney Diseases: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Aymé S, Bockenhauer D, Day S, Devuyst O, Guay-Woodford LM, Ingelfinger JR, Klein JB, Knoers NVAM, Perrone RD, Roberts J, Schaefer F, Torres VE, Cheung M, Wheeler DC, Winkelmayer WC; Conference Participants.

Kidney Int. 2017 Oct;92(4):796-808. doi: 10.1016/j.kint.2017.06.018. Erratum in: Kidney Int. 2017 Dec;92(6):1558.

Supplemental Content

Loading ...
Support Center